See the DrugPatentWatch profile for Izervay
Izervay is a medication used to treat a specific type of cancer. It is a targeted therapy that works by inhibiting certain proteins involved in cancer cell growth [1].
How does Izervay work?
Izervay targets the FGFR (fibroblast growth factor receptor) family of proteins. In some cancers, these receptors are overactive or mutated, driving tumor growth. By blocking these abnormal FGFR signals, Izervay aims to slow or stop the cancer from progressing [1].
What types of cancer is Izervay approved for?
Izervay is approved for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement [1].
When was Izervay approved?
The U.S. Food and Drug Administration (FDA) approved Izervay on December 1, 2022 [1].
What is the typical dosage for Izervay?
The recommended starting dose for Izervay is 100 mg taken orally twice daily [1].
What are the potential side effects of Izervay?
Common side effects of Izervay can include dry eye, mouth sores, diarrhea, fatigue, nausea, changes in nail condition, hair loss, and decreased appetite. Serious side effects may involve eye problems, including dry eye and inflammation of the eye, as well as potential harm to a developing fetus [1].
Are there any specific warnings or precautions for Izervay?
Yes, Izervay carries warnings regarding ocular toxicity, including dry eye and uveitis, which may require dose adjustments or discontinuation. It also carries a warning about embryofetal toxicity, meaning it can cause harm to a fetus, and is not recommended for use during pregnancy [1].
What are the drug interactions with Izervay?
Information on specific drug interactions for Izervay is available in its prescribing information. Patients should inform their doctor about all medications they are taking, including over-the-counter drugs and herbal supplements [1].
How is Izervay administered?
Izervay is taken orally, meaning it is swallowed as a pill [1].
What is the prognosis for patients treated with Izervay?
Clinical trials have shown that Izervay can help control the growth of FGFR2-driven cholangiocarcinoma. The overall prognosis depends on various factors, including the stage of the cancer and the individual patient's response to treatment [1].
Where can I find more detailed information about Izervay?
More comprehensive information, including full prescribing details and clinical trial data, is available on the DrugPatentWatch.com website [1].